Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.30 |
| ▸ | BAD | Q92934 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13106424 | 0.83 | GAA (0.33) | MAPK8MAPK9MAPK10BRD9PDE10A | |
| SCHEMBL13106438 | 0.83 | MAPK8 (0.43) | MAPK8MAPK9MAPK10BRD9GAA | |
| SCHEMBL13106443 | 0.82 | GAA (0.36) | MAPK8MAPK9MAPK10GAAOPRL1 | |
| SCHEMBL13106366 | 0.82 | MAPK8 (0.36) | MAPK8MAPK9MAPK10GAA | |
| SCHEMBL13106360 | 0.81 | MAPK8 (0.36) | MAPK8MAPK9MAPK10GAA | |
| SCHEMBL13106308 | 0.78 | ADORA2A (0.41) | MAPK8MAPK9PDE10APTGDR2HTR2A | |
| SCHEMBL13106432 | 0.77 | MAPK8 (0.41) | MAPK8MAPK9MAPK10BRD9GAA | |
| SCHEMBL13106356 | 0.73 | ESR1 (0.43) | MAPK8MAPK9MAPK10 | |
| SCHEMBL13106445 | 0.72 | MAPK8 (0.42) | MAPK8MAPK9MAPK10GAA | |
| SCHEMBL13106364 | 0.72 | GAA (0.36) | MAPK8MAPK9MAPK10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812045-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2010-10-12 | — | — | US | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | MAPK8 3107/4885MAPK9 2234/4885MAPK10 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.